These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 34396444)

  • 1. Cucurbitacin B enhances apoptosis in gefitinib resistant non‑small cell lung cancer by modulating the miR‑17‑5p/STAT3 axis.
    Yu B; Zheng L; Tang H; Wang W; Lin Y
    Mol Med Rep; 2021 Oct; 24(4):. PubMed ID: 34396444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cucurbitacin B Induces the Lysosomal Degradation of EGFR and Suppresses the CIP2A/PP2A/Akt Signaling Axis in Gefitinib-Resistant Non-Small Cell Lung Cancer.
    Liu P; Xiang Y; Liu X; Zhang T; Yang R; Chen S; Xu L; Yu Q; Zhao H; Zhang L; Liu Y; Si Y
    Molecules; 2019 Feb; 24(3):. PubMed ID: 30759826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Axl is a novel target of celastrol that inhibits cell proliferation and migration, and increases the cytotoxicity of gefitinib in EGFR mutant non‑small cell lung cancer cells.
    Lee YJ; Kim SY; Lee C
    Mol Med Rep; 2019 Apr; 19(4):3230-3236. PubMed ID: 30816529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MiR-133a-3p attenuates resistance of non-small cell lung cancer cells to gefitinib by targeting SPAG5.
    Li Q; Wang Y; He J
    J Clin Lab Anal; 2021 Jul; 35(7):e23853. PubMed ID: 34057242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel circ_MACF1/miR-942-5p/TGFBR2 axis regulates the functional behaviors and drug sensitivity in gefitinib-resistant non-small cell lung cancer cells.
    Fan D; Yang Y; Zhang W
    BMC Pulm Med; 2022 Jan; 22(1):27. PubMed ID: 34996416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer.
    Sun C; Gao W; Liu J; Cheng H; Hao J
    Respir Res; 2020 Aug; 21(1):210. PubMed ID: 32778129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Shenqi Fuzheng injection restores the sensitivity to gefitinib in non-small cell lung cancer by inhibiting the IL-22/STAT3/AKT pathway.
    Wang J; He X; Jia Z; Yan A; Xiao K; Liu S; Hou M; Long Y; Ding X
    Pharm Biol; 2024 Dec; 62(1):33-41. PubMed ID: 38100532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship between miR-17-5p, miR-92a, and let-7b expression with non-small cell lung cancer targeted drug resistance.
    Gong J; He L; Ma J; Zhang J; Wang L; Wang J
    J BUON; 2017; 22(2):454-461. PubMed ID: 28534369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cucurbitacin B regulates lung cancer cell proliferation and apoptosis
    Liu JH; Li C; Cao L; Zhang CH; Zhang ZH
    Pharm Biol; 2022 Dec; 60(1):154-162. PubMed ID: 34967707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LncRNA HOST2 enhances gefitinib-resistance in non-small cell lung cancer by down-regulating miRNA-621.
    Chen ZY; Liu HY; Jiang N; Yuan JM
    Eur Rev Med Pharmacol Sci; 2019 Nov; 23(22):9939-9946. PubMed ID: 31799663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. let‑7 and miR‑17 promote self‑renewal and drive gefitinib resistance in non‑small cell lung cancer.
    Yin J; Hu W; Pan L; Fu W; Dai L; Jiang Z; Zhang F; Zhao J
    Oncol Rep; 2019 Aug; 42(2):495-508. PubMed ID: 31233201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MiR-873 inhibition enhances gefitinib resistance in non-small cell lung cancer cells by targeting glioma-associated oncogene homolog 1.
    Jin S; He J; Li J; Guo R; Shu Y; Liu P
    Thorac Cancer; 2018 Oct; 9(10):1262-1270. PubMed ID: 30126075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. STAT3 inhibitor BBI608 enhances the antitumor effect of gefitinib on EGFR-mutated non-small cell lung cancer cells.
    Wang Q; Lu B; Zhang Y; Yu J; Guo J; Zhou Q; Lv H; Sun Y
    Hum Cell; 2021 Nov; 34(6):1855-1865. PubMed ID: 34370268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MiR-142-5p reverses the resistance to gefitinib through targeting HOXD8 in lung cancer cells.
    Zhu W; Wang JP; Meng QZ; Zhu F; Hao XF
    Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4306-4313. PubMed ID: 32373967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism research of miR-34a regulates Axl in non-small-cell lung cancer with gefitinib-acquired resistance.
    Xiong R; Sun XX; Wu HR; Xu GW; Wang GX; Sun XH; Xu MQ; Xie MR
    Thorac Cancer; 2020 Jan; 11(1):156-165. PubMed ID: 31777195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. lincRNA‑p21 inhibits the progression of non‑small cell lung cancer via targeting miR‑17‑5p.
    Ao X; Jiang M; Zhou J; Liang H; Xia H; Chen G
    Oncol Rep; 2019 Feb; 41(2):789-800. PubMed ID: 30535441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC).
    Codony-Servat C; Codony-Servat J; Karachaliou N; Molina MA; Chaib I; Ramirez JL; de Los Llanos Gil M; Solca F; Bivona TG; Rosell R
    Oncotarget; 2017 Jul; 8(29):47305-47316. PubMed ID: 28521301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer.
    Jang JY; Kim YG; Nam SJ; Keam B; Kim TM; Jeon YK; Kim CW
    Mol Cancer Ther; 2016 Jun; 15(6):1387-96. PubMed ID: 26883272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heptadecanoic acid inhibits cell proliferation in PC‑9 non‑small‑cell lung cancer cells with acquired gefitinib resistance.
    Xu C; Wu P; Gao J; Zhang L; Ma T; Ma B; Yang S; Shao G; Yu Y; Huang X; Yang X; Zhang B
    Oncol Rep; 2019 Jun; 41(6):3499-3507. PubMed ID: 31002344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance.
    Zheng Q; Dong H; Mo J; Zhang Y; Huang J; Ouyang S; Shi S; Zhu K; Qu X; Hu W; Liu P; Wang Y; Zhang X
    Theranostics; 2021; 11(2):824-840. PubMed ID: 33391507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.